CME earnings analysis
What we found in CME's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
CME posted record Q2 revenue of $1.706 billion, up 1% year over year, and GAAP diluted EPS of $2.88, up 2%, but both revenue and earnings declined from Q1 2026 as market volatility normalized. Market-data revenue grew 20% and equity-index activity was strong, but lower clearing volumes and a 2% decline in average rate per contract reduced core transaction-fee revenue by 3%. Operating margin contracted 180 basis points to 64.9% amid 6% expense growth, while first-half operating cash flow remained strong at $2.207 billion; no formal quantitative guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and EPS grew modestly year over year
- Q2 revenue rose 1% year over year to $1,706.2 million, while net income increased 2% to $1,041.8 million and GAAP diluted EPS rose $0.07 to $2.88 from $2.81. Revenue was down sequentially from $1,880.1 million in Q1 2026, and EPS declined from $3.18.
- Market data delivered 20% growth
- Market-data and information-services revenue increased 20% to $238.1 million, driven by higher product usage, demand from new customer segments, and price increases. This offset a 3% decline in clearing and transaction fees to $1,352.5 million.
- Equity and crypto volumes expanded
- Equity-index ADV increased 13% to 8.634 million contracts per day, led by E-mini Nasdaq-100 volume up 32% to 3.191 million. Bitcoin futures and options ADV increased 35% to 116 thousand contracts per day.
- Operating cash flow remained robust
- First-half operating cash flow increased 1% to $2,207.0 million from $2,175.1 million. CME attributed the increase primarily to greater trading volume and higher collateral-reinvestment interest income net of distributions.
- Strong committed liquidity capacity
- Liquidity remained substantial: CME had approximately $2.3 billion of unused general-corporate revolving capacity at June 30 and no borrowings under that facility. Its $7.0 billion clearing-house facility also had no outstanding borrowings, with $10.3 billion of guaranty-fund contributions available as collateral.
- Capital return accelerated through buybacks
- CME repurchased 2,546,284 shares under its authorization during April through June 2026, leaving $1,504.4 million available under the $3.0 billion program at quarter-end.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Expense growth compressed operating margin
- Operating margin fell 180 basis points year over year to 64.9% from 66.7%, and declined from 69.7% in Q1 2026. Total expenses increased 6% to $599.1 million, including technology expense up 18% to $83.3 million and licensing/other fee agreements up 13% to $109.1 million.
- Core transaction-fee revenue declined
- Clearing and transaction fees fell 3% to $1,352.5 million as total futures/options volume declined 1% to 1,850.2 million contracts and average rate per contract fell 2% to $0.678. Management cited increased micro-contract activity and a higher member-trading mix as rate headwinds.
- Corporate cash balance fell materially
- Cash and cash equivalents decreased $2.3 billion to $2.1 billion at June 30, 2026, from $4.4 billion at December 31, 2025. Financing cash outflows rose in the first half because of increased share repurchases.
- Lower volatility pressured key product volumes
- Energy ADV declined 13% to 2.667 million contracts per day, interest-rate ADV declined 6% to 14.532 million, and FX ADV declined 10% to 989 thousand. Management attributed the Q2 declines principally to lower volatility and greater certainty around Federal Reserve policy after unusually volatile earlier periods.
- No material risk-factor updates disclosed
- The filing reports 0 material changes to risk factors from the February 26, 2026 Form 10-K. It also reports no material change in market-risk exposure since December 31, 2025, so there is no newly disclosed risk-factor update to underwrite.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.88
- Operating margin
- 64.9%
- Segment
- Clearing and transaction fees: $1,352.5 million, down 3% year over year
- Segment
- Market data and information services: $238.1 million, up 20% year over year
- Segment
- Other revenue: $115.6 million, up 9% year over year
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS outlook. Management states that it expects to maintain an investment-grade rating, supported by cash-flow generation, ability to pay down debt, and refinancing capacity.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 24, 2026
- CME reported a strong Q1 2026 with total revenue of $1,880.1 million (up 14% YoY), diluted EPS of $3.18 (up 21% YoY) and operating margin expanding to 69.7% from 67.5% a year ago. Volume drove results: total contract…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CME makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever